Tafasitamab: all 43 studies that test it
Page 1 of 1. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.
- Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular LymphomaRecruitingNCT07731789Phase 2
- A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideNot yet recruitingNCT07585747Phase 2
- Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNot yet recruitingNCT07582159Phase 2
- TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaNot yet recruitingNCT07502872Phase 2
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)RecruitingNCT07225439Phase 1
- Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaRecruitingNCT07126236Phase 2
- HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLRecruitingNCT06792825Phase 2
- Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell LymRecruitingNCT06760156Phase 2
- Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06521255Phase 3
- Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With TafasitamabRecruitingNCT06465433Phase 2
- Zanubrutinib and Tafasitamab in Mantle Cell LymphomaRecruitingNCT06029309Phase 1/2
- Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingNCT05943496Phase 1
- Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT05910801Phase 2
- Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative DisorderRecruitingNCT05786040Phase 2
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLRecruitingNCT05615636Phase 2
- Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSLRecruitingNCT05583071Phase 2
- Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCLRecruitingNCT05552937Phase 2
- Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage LeukemiaRecruitingNCT05366218Phase 1/2
- Tafasitamab Plus Lenalidomide in Relapsed CNS LymphomaRecruitingNCT05351593Phase 1/2
- A Study of Tafasitamab and Lenalidomide in People With Mantle Cell LymphomaTerminatedNCT05788289Phase 2Results posted
- Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaTerminatedNCT05626322Phase 1/2Results posted
- Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL PatientsActive, not recruitingNCT05222555Phase 1/2Results posted
- A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)TerminatedNCT04809467Phase 1/2Results posted
- A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.Active, not recruitingNCT04680052Phase 3Results posted
- Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCLCompletedNCT04134936Phase 1Results posted
- A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT02763319Phase 2/3Results posted
- Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCLCompletedNCT02399085Phase 2Results posted
- Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)TerminatedNCT01685021Phase 2Results posted
- Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)CompletedNCT01685008Phase 2Results posted
- A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell LymphomaWithdrawnNCT07030699Phase 2
- Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell LymphomaActive, not recruitingNCT05821088Phase 2
- Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL StudyActive, not recruitingNCT05718869Phase 2
- Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaActive, not recruitingNCT05455697Phase 1/2
- Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic LeukemiaActive, not recruitingNCT05453500Phase 2
- Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)Active, not recruitingNCT05429268Phase 3
- A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.WithdrawnNCT05205252Phase 1/2
- Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop StudyActive, not recruitingNCT04978584Phase 2
- Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or OlderActive, not recruitingNCT04974216Phase 2
- Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell LymphomaWithdrawnNCT04882163Phase 1/2
- Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsActive, not recruitingNCT04824092Phase 3
- Study of Acalabrutinib and Tafasitamab in MZL PatientsActive, not recruitingNCT04646395Phase 2
- Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell LymphomaActive, not recruitingNCT04161248Early Phase 1
- Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic LeukemiaCompletedNCT01161511Phase 1